Fresenius Medical Care AG & Co. KGaA (FME) AI Stock Analysis

• Market Cap: €12.32B
• Dividend Yield: 3.4%
• Average Volume (3M): 587.63K
• Price to Earnings (P/E): 18.8
• Beta (1Y): 0.79
• Revenue Growth: 0.53%
• EPS Growth: 23.79%
• Country: DE
• Employees: 112,035
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Care Facilities
• EPS (TTM): 0.91
• Shares Outstanding: 293,413,450
• 10 Day Avg. Volume: 642,533
• 30 Day Avg. Volume: 587,626
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €48.63
• Price Target Upside: 13.49% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 13

• Rating: 66 Neutral
• Price Target: €46.00 ▲(7.35% Upside)

Fresenius Medical Care AG & Co. KGaA's overall stock score is driven primarily by its strong financial performance and fair valuation. However, technical indicators suggest a lack of upward momentum, which tempers the overall score.

Positive Factors

Clinical Efficiency

The CONVINCE trial showed a 22% reduction in mortality, highlighting the clinical efficiency and patient benefit of the 5008x rollout.

Cost Management

Fresenius continues to execute on FME25 savings, achieving strong traction with €128mn in the first half against an annual target of €180mn.

Strategic Initiatives

The first tranche of the buyback is planned to begin, and the HV HDF rollout is positioned to begin soon, which are positive updates.

Negative Factors

Foreign Exchange Impact

Estimates for FY25/FY26 are being lowered by 1-3% due to expected foreign exchange headwinds of 3-4% in FY25.

Investor Concerns

The lack of guideline for mid-term topline growth is the largest area of investor concern, especially with structural challenges.

Market Reaction

Expectations were running high into the CMD, and the updated targets were largely factored into the share price, resulting in a 'sell the news' reaction with shares down 5%.

Fresenius Medical Care AG & Co. KGaA Business Overview & Revenue Model

Company Description

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

How the Company Makes Money

Fresenius Medical Care generates revenue primarily through two key streams: the sale of dialysis products and the provision of dialysis services. The product segment includes the manufacturing and distribution of dialysis machines, dialyzers, and other related consumables, which are sold to hospitals, clinics, and other healthcare providers. The service segment involves the operation of a vast number of dialysis clinics globally, where patients receive treatment on a regular basis. Revenue from services is typically derived from reimbursement payments from government programs, private insurers, and out-of-pocket payments from patients. Additionally, the company benefits from partnerships with healthcare providers and payers, which can enhance its service delivery and expand its market reach. Factors such as an aging population, the increasing prevalence of chronic kidney disease, and advancements in dialysis technology also contribute to its earnings potential.

Fresenius Medical Care AG & Co. KGaA Financial Statement Overview

Summary

Fresenius Medical Care shows stable financial performance with consistent revenue and profit margins, a balanced capital structure, and strong cash generation capabilities. However, growth is relatively flat, and leverage remains moderately high.

Income Statement

Fresenius Medical Care experienced a slight revenue decline of approximately 0.6% from 2023 to 2024, following a similar trend from previous years. Despite this, the company maintained a strong gross profit margin of around 24.6% in 2024, reflecting efficient cost management. However, the net profit margin decreased slightly from 2.6% in 2023 to 2.8% in 2024. The EBIT margin improved slightly, indicating better operational profitability. Overall, the income statement reveals stable but not strong growth, with consistent margins indicating good operational efficiency.

Balance Sheet

The balance sheet shows a debt-to-equity ratio of approximately 0.75 in 2024, indicating a moderate level of leverage. The equity ratio of 43.4% suggests a balanced capital structure, though slightly lower than desirable for long-term stability. The return on equity (ROE) improved to 3.7% in 2024, reflecting better profitability. Overall, the balance sheet indicates adequate financial health with manageable leverage, but there is room for improvement in equity levels and returns.

Cash Flow

In 2024, operating cash flow decreased by 9.2% compared to 2023, yet free cash flow remained strong. The free cash flow to net income ratio was significant, indicating good cash generation relative to profits. However, the decrease in operating cash flow and free cash flow compared to previous years suggests potential challenges in maintaining cash generation levels. Overall, the cash flow statement shows a solid cash position but highlights the need for improved cash flow growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	19.52B	19.34B	19.45B	19.40B	17.62B	17.86B
Gross Profit	4.81B	4.76B	4.93B	5.31B	5.08B	5.54B
EBITDA	3.09B	3.21B	2.93B	3.22B	3.42B	3.83B
Net Income	656.43M	537.91M	499.00M	673.40M	969.31M	1.16B
Balance Sheet
Total Assets	31.29B	33.57B	33.93B	35.75B	34.37B	31.69B
Cash, Cash Equivalents and Short-Term Investments	2.19B	1.45B	1.54B	1.44B	1.62B	1.24B
Total Debt	11.02B	10.98B	12.05B	13.21B	13.32B	12.38B
Total Liabilities	16.96B	17.80B	19.10B	20.30B	20.39B	19.36B
Stockholders Equity	13.27B	14.58B	13.62B	15.45B	13.98B	12.33B
Cash Flow
Free Cash Flow	2.05B	1.69B	1.94B	1.44B	1.64B	2.15B
Operating Cash Flow	2.75B	2.39B	2.63B	2.17B	2.49B	4.23B
Investing Cash Flow	-578.46M	-84.94M	-544.23M	-734.73M	-1.20B	-1.33B
Financing Cash Flow	-1.51B	-2.57B	-1.86B	-1.62B	-1.02B	-2.66B

Fresenius Medical Care AG & Co. KGaA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 42.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:FME, the sentiment is Negative. The current price of 42.85 is below the 20-day moving average (MA) of 42.90, below the 50-day MA of 44.21, and below the 200-day MA of 44.85, indicating a bearish trend. The MACD of -0.45 indicates Negative momentum. The RSI at 47.61 is Neutral, neither overbought nor oversold. The STOCH value of 44.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:FME.

Fresenius Medical Care AG & Co. KGaA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FME	66 Neutral	€12.32B	18.77	4.83%	3.40%	0.53%	23.79%
Sector *	51 Neutral	$7.93B	-0.32	-43.43%	2.21%	22.30%	-1.88%
0P6S	―	€27.75B	―	-10.35%	―	―	―
0DHC	―	€3.70B	23.38	7.48%	―	―	―
0O14	―	€47.63B	16.64	10.08%	―	―	―
0NIR	―	€12.29B	129.56	3.88%	―	―	―
SEMHF	―	$62.06B	26.39	11.75%	1.72%	―	―